Potential role of statins in inflammation and atherosclerosis
M Yoshida - Journal of atherosclerosis and thrombosis, 2003 - jstage.jst.go.jp
The beneficial effects of 3-hydroxyl-3-methyl-CoA (HMG-CoA) reductase inhibitors, or
statins, on cardiovascular diseases are now widely recognized from an increasing large …
statins, on cardiovascular diseases are now widely recognized from an increasing large …
The anti-atherosclerotic effects of lipid lowering with atorvastatin in patients with hypercholesterolemia
K Ozaki, T Kubo, R Imaki, H Shinagawa… - … of atherosclerosis and …, 2006 - jstage.jst.go.jp
A large-scale epidemiological study showed clinically that hyperlipidemia is one of the major
risk factors for atherosclerosis and coronary heart disease1). In addition, various large-scale …
risk factors for atherosclerosis and coronary heart disease1). In addition, various large-scale …
Current thinking in statin therapy
P Puddu, GM Puddu, A Muscari - Acta cardiologica, 2001 - Taylor & Francis
The HMG-CoA reductase inhibitors (statins) are now considered the most potent lipid-
lowering drugs. Treatment with statins reduces both morbidity and mortality rates due to …
lowering drugs. Treatment with statins reduces both morbidity and mortality rates due to …
Anti-atherosclerotic effects of statins: lessons from prevention trials
Statins are best-known for their lipid-lowering effects and have been shown to significantly
impact the natural progression of coronary atherosclerosis. The mechanism through which …
impact the natural progression of coronary atherosclerosis. The mechanism through which …
Effect of Atorvastatin on Haemostasis, Fibrinolysis and Inflammation in Normocholesterolaemic Patients with Coronary Artery Disease: A Post Hoc Analysis of Data …
T Walter, S Szabo, T Suselbeck, M Borggrefe… - Clinical drug …, 2010 - Springer
Abstract Background: Treatment with HMG-CoA reductase inhibitors (statins) reduces the
morbidity and mortality of coronary artery disease (CAD). In addition to their lipid-lowering …
morbidity and mortality of coronary artery disease (CAD). In addition to their lipid-lowering …
New evidence for beneficial effects of statins unrelated to lipid lowering
W Palinsk - Arteriosclerosis, thrombosis, and vascular biology, 2001 - Am Heart Assoc
Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (statins)
constitute the single most powerful class of hypolipidemic drugs currently available. Their …
constitute the single most powerful class of hypolipidemic drugs currently available. Their …
A brief review paper of the efficacy and safety of atorvastatin in early clinical trials
RG Bakker-Arkema, J Best, R Fayyad, TM Heinonen… - Atherosclerosis, 1997 - Elsevier
Preclinical and clinical data on atorvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A
(HMG-CoA) reductase inhibitor, indicate that it has superior activity in treating a variety of …
(HMG-CoA) reductase inhibitor, indicate that it has superior activity in treating a variety of …
Is atorvastatin superior to other statins? Analysis of the clinical trials with atorvastatin having cardiovascular endpoints
SA Doggrell - Reviews on recent clinical trials, 2006 - ingentaconnect.com
Placebo-controlled clinical trials have shown that atorvastatin is beneficial in patients with
myocardial ischemia, established coronary artery disease, hypertension and 3 other …
myocardial ischemia, established coronary artery disease, hypertension and 3 other …
The Treatment of Coronary Heart Disease: An Update
G Kolovou - Current medical research and opinion, 2001 - Taylor & Francis
Statins may have additional properties beyond diminishing low-density lipoprotein (LDL)
cholesterol levels. These actions could reduce the risk of vascular events. For example …
cholesterol levels. These actions could reduce the risk of vascular events. For example …